Skip to main content
. 2021 Feb 11;12:638096. doi: 10.3389/fmicb.2021.638096

FIGURE 4.

FIGURE 4

Schematic representation of gene replacement by the CRISPR/Cas9 strategy. The mutant retained the capability to produce pneumocandin B0, while the production of pneumocandin C0 was abolished.